SSY Group Limited — Earnings Release 2014

Apr 24, 2014

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [308 x 113] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2014

The Company announces the turnover and gross profit information, which has not been reviewed by its auditors, for the three months ended 31 March 2014.

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) announces the financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2014 based on its management accounts which have not been reviewed by the auditors.

Turnover of the Group, which has not been reviewed by the auditors, for the three months ended 31 March 2014 increased by 14.6% as compared with the same period of 2013 to HK$808 million, with gross profit margin of 46.8% (for the three months ended 31 March 2013: 44.1%) and in particular:

• Turnover of Intravenous infusion solution business segment for the first three months in 2014 increased by approximately 19.1% as compared with the same period of 2013 to HK$474 million, with gross profit margin of 49.6% (for the three months ended 31 March 2013: 45.0%). Among which, sales of Non-PVC Soft Bag infusion solution was HK$251 million, representing 58.8% of the sales of intravenous infusion solution and an increase of 40.2% as compared with the same period of 2013; sales of PP Plastic Bottle infusion solution was HK$132 million, representing 30.9% of the sales of intravenous infusion solution and an increase of 8.5% as compared with the same period of 2013; and

— 1 —

• Turnover of Antibiotics finished medicines business segment and Non-antibiotics finished medicines business segment for the first three months in 2014 increased by approximately 14.5% to HK$204 million and increased by approximately 0.9% to HK$131 million respectively as compared with the same period of 2013, with the aggregated gross profit margin of 42.9% (for the three months ended 31 March 2013: 42.9%); among which, sales of Lijunsha amounted to HK$137 million, represented an increase of 47.3% as compared with the same period of 2013; sales of Paiqi amounted to HK$26.04 million, represented a decrease of 31.1% as compared with the same period of 2013; sales of Dobesilate amounted to HK$23.53 million, represented an increase of 48.6% as compared with the same period of 2013; sales of Lixiding amounted to HK$11.20 million, represented an increase of 8.3% as compared with the same period of 2013.

In terms of business segments analysis, Intravenous infusion solution, Antibiotics finished medicines and Non-antibiotics finished medicines accounted for approximately 58.6%, 25.2% and 16.2% respectively of the total turnover of the Group, which has not been reviewed by the auditors, for the first three months in 2014 (for the three months ended 31 March 2013: 56.4%, 25.2% and 18.4% respectively).

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board Chan Ka Kit Company Secretary

Hong Kong, 23 April 2014

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

— 2 —